Investment & Fund Management

Clariness, a healthcare company based in Germany, faced significant challenges in the clinical trials sector, particularly the lengthy timelines associated with bringing new drugs to market. Co-founder and CEO Michael Stadler highlighted that the efficiency and safety of clinical trials depend on recruiting a sufficient number of patients, and delays can cost pharmaceutical companies up to a million euros per day. The company aimed to reduce the time it takes to conduct clinical trials by 3 to 8 months, thereby enhancing the availability of new drugs to patients in need.

To address these challenges, Clariness developed ClinLife, a user-friendly platform that connects patients with relevant clinical studies based on their medical conditions. This innovative solution not only facilitates the recruitment and retention of trial participants but also provides patients with insights derived from live data. The platform aims to increase transparency and accessibility in the clinical trials space, akin to a booking platform for clinical studies.

In mid-2019, Clariness secured an equity investment from Rocket Internet Capital Partners, supported by the European Investment Fund (EIF) under the EU’s Investment Plan for Europe. This funding enabled the company to further develop its product and expand its operations, including opening an office in China. As a result of these efforts, Clariness has experienced significant growth, with up to 42 million visits annually across 50 countries and 35 languages. The company is also poised to play a crucial role in addressing urgent health challenges, such as the development of a Covid-19 vaccine, with trials expected to commence shortly.